Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors [Clinical Trials]

Nivolumab plus ipilimumab achieves higher response rates than previously reported for nivolumab alone.

http://ift.tt/2oDOuNO